犹太裔以色列BRCA突变携带者生育治疗与乳腺癌风险
该历史队列研究纳入1824例犹太裔以色列BRCA1/2突变携带者,其中332例接受生育治疗。多因素分析未发现生育治疗与乳腺癌风险相关,但父源突变和口服避孕药超过5年与乳腺癌风险升高相关,任何口服避孕药使用与卵巢癌风险降低相关。
要点
- 生育治疗未显著增加BRCA1/2突变携带者的乳腺癌风险。
- 父源突变和口服避孕药超过5年与乳腺癌风险升高相关。
- 任何口服避孕药使用与卵巢癌风险降低相关。
核心结论
- 生育治疗未导致BRCA1/2突变携带者乳腺癌风险明显增加。
研究设计与样本
- 历史队列研究,纳入1824例犹太裔以色列BRCA1/2突变携带者,其中332例接受生育治疗。
主要发现
- 687例携带者确诊乳腺癌;生育治疗与乳腺癌风险无关联,克罗米芬HR 0.77(95%CI 0.49-1.19),促性腺激素HR 0.54(95%CI 0.28-1.01),IVF HR 0.65(95%CI 0.39-1.08),联合治疗HR 1.23(95%CI 0.49-3.06)。
- 父源突变与乳腺癌风险升高相关(HR 1.43,95%CI 1.17-1.75)。
- 口服避孕药使用超过5年与乳腺癌风险升高相关(HR 1.62,95%CI 1.27-2.06)。
- 任何口服避孕药使用与卵巢癌风险降低相关(HR 0.61,95%CI 0.46-0.82)。
临床怎么用
- BRCA1/2突变携带者接受生育治疗时,无需因乳腺癌风险而过度担忧。
- 应关注父源突变和长期口服避孕药使用者的乳腺癌风险。
局限性
- 单中心历史队列研究,结果需更多人群验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether fertility treatments impact the risk of breast cancer in Jewish Israeli BRCA1/2 mutation carriers. DESIGN: Historical cohort study. SETTING: University-affiliated tertiary medical center. PATIENT(S): A total of 1,824 Jewish Israeli BRCA1/2 mutation carriers from a single center were stratified into 1,492 (81.8%) carriers who were not treated for infertility and 332 (18.2%) carriers who underwent fertility treatment with clomiphene citrate (n = 134), gonadotropin (n = 119), in vitro fertilization (n = 183), or a combination of treatments (n = 89). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Hazard ratios (HR) and 95% confidence intervals (CI) for the association of breast cancer with fertility treatment and other hormonal and reproductive variables. RESULT(S): Breast cancer was diagnosed in 687 BRCA1/2 mutation carriers. Multivariate analysis, either of the whole group or stratified by each gene, showed no association between fertility treatment and breast cancer risk, regardless of the type of treatment (clomiphene citrate: HR 0.77, 95% CI 0.49-1.19; gonadotropin: HR 0.54, 95% CI 0.28-1.01; in vitro fertilization: HR 0.65, 95% CI 0.39-1.08; and combined treatments: HR 1.23, 95% CI 0.49-3.06). An increased breast cancer risk was associated with paternal origin of the mutation (HR 1.43, 95% CI 1.17-1.75) and use of oral contraceptives for >5 years (HR 1.62, 95% CI 1.27-2.06) in both BRCA1 and BRCA2 mutation carriers. Ovarian cancer risk was decreased with the use of any oral contraceptive (HR 0.61; 95% CI 0.46-0.82). CONCLUSION(S): Fertility treatment for BRCA1/2 mutation carriers is not associated with a discernible increase in breast cancer risk.
引用
- Perri T, Naor-Revel S, Eliassi-Revivo P, et al. Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertil Steril. 2021. PMID: 33823990. doi:10.1016/j.fertnstert.2021.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。